Patents Examined by Karlheinz R. Skowronek
  • Patent number: 10854326
    Abstract: A method for predicting drug concentration levels includes receiving at least one subject characteristic of the subject, and executing a full body circulation model by: determining a first concentration of the drug in a first blood flow entering a first organ determining a second concentration of the drug in the first organ, determining a third concentration of a drug in a third blood flow entering a second organ, the third blood flow downstream of the first organ, and determining, using the second organ model a fourth concentration of the drug in the second organ.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: December 1, 2020
    Assignee: VERISIM LIFE INC.
    Inventor: Jyotika Varshney
  • Patent number: 10766939
    Abstract: The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 8, 2020
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Oliver Demmer, Lise Giehm, Jesper Sloth Villadsen, Henrik Munch, Jesper Mosolff Mathiesen, Jolanta Skarbaliene, Maria Deryabina, Dieter Wolfgang Hamprecht
  • Patent number: 10670600
    Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: June 2, 2020
    Assignee: Children's Medical Center Corporation
    Inventor: Randolph Watnick
  • Patent number: 10647747
    Abstract: The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: May 12, 2020
    Assignee: S&T GLOBAL INC.
    Inventors: Zhuang Su, Zhengyu Long, Zhennian Huang, Suizhou Yang
  • Patent number: 10604779
    Abstract: Disclosed is a highly efficient method for production of highly pure mutant-type human erythropoietin. The method is for production of mutant-type human erythropoietin, in which a transformed mammalian cell is allowed to produce the mutant-type human erythropoietin, and the supernatant of the culture is subjected to hydrophobic column chromatography, multimodal anion exchange column chromatography, anion exchange column chromatography, phosphate group affinity column chromatography, and gel filtration column chromatography, in this order.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: March 31, 2020
    Inventors: Shinji Kakimoto, Miroslav Matev, Tsuyoshi Fukui, Yukichi Hatano, Junya Tani, Kazutoshi Mihara, Kenichi Takahashi, Atsushi Sugimura
  • Patent number: 10598667
    Abstract: The present invention provides kits and methods for detecting peptides that change of the fluorescence of dyes upon binding to the dye. In addition, the invention provides methods for identifying said peptides.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: March 24, 2020
    Inventors: Kit S. Lam, Lin Tian, Sara Ahadi, Ruiwu Liu
  • Patent number: 10577405
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 3, 2020
    Assignee: Mederis Diabetes LLC
    Inventor: John J. Nestor
  • Patent number: 10568992
    Abstract: The present invention relates to the production of endothelialized matrices and materials from immature endothelial cells using substrates to which particular peptides have been grafted. The resultant substrates can be used to capture and support immature endothelial cells. Further, the methods and compositions of the present invention provide viable cell delivery platforms that allow for production and provision of endothelialized medical devices and implants, including vascular grafts, stents, shunts, and valves, endothelialized surfaces and channels for in vitro testing devices, including microfluidic chips, and materials that support vascularization such as for use in engineered tissues. The present invention includes novel methods required for the successful production of cellularized substrates, systems and components used for the same, and methods of using the resultant cell and tissue compositions.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: February 25, 2020
    Assignee: Auburn University
    Inventors: Elizabeth A. Lipke, Wen Jun Seeto
  • Patent number: 10570188
    Abstract: Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (Bn-CSo-Is-CSp-FC-CSq-ItCSr-Bm)u, wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 25, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Martin Bader, Stefan Dengl, Stefan Lorenz, Stefan Seeber
  • Patent number: 10570189
    Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: February 25, 2020
    Assignee: PFIZER INC.
    Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
  • Patent number: 10562952
    Abstract: Chimeric antigen receptors (CARs) that specifically bind to and immunologically recognize CD276 are disclosed. Related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: February 18, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Crystal L. Mackall, Yongzhi Karen Cui
  • Patent number: 10556924
    Abstract: The present invention relates to a novel process for the preparation of Pasireotide of formula 11 [Cyclo [Phe-{4-(OCO—NH—CH2—CH2—NH2)) Pro}-Phg-DTrp-Lys-Tyr(Bzl)]]. The invention also relates to a novel intermediate compound of formula 8 and process thereof which is used for preparation of compound of formula 11.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: February 11, 2020
    Inventors: Manik Reddy Pullagurla, Radha Nagarapu, Jagadeesh Babu Rangisetty
  • Patent number: 10555988
    Abstract: The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: February 11, 2020
    Assignee: Chain Antimicrobials Oy
    Inventors: Tejesvi Mysore Vishakante Gowda, Anna Maria Pirttilä
  • Patent number: 10543256
    Abstract: Physically and chemically stable pharmaceutical formulations in the form of an aqueous suspension comprising a reconstituted pulmonary surfactant are useful for the prophylaxis and/or treatment of respiratory distress syndrome (RDS) and other respiratory disorders.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: January 28, 2020
    Inventors: Franco Sartor, Marisa Pertile, Annamaria Soliani Raschini
  • Patent number: 10543255
    Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: January 28, 2020
    Inventors: Scott Shandler, Samuel H. Gellman, John M. Gledhill
  • Patent number: 10532105
    Abstract: Novel amphiphilic peptide, peptide amphiphile lipid micelles, processes for making peptide amphiphile lipid micelles comprising an amphiphilic peptide and phospholipid and optionally comprising a cargo molecule, and methods of use.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: January 14, 2020
    Assignee: Peptinovo Biopharma, LLC.
    Inventors: Reynold Homan, William L. Elliott
  • Patent number: 10533037
    Abstract: The invention discloses a freeze-dried powder of high molecular weight silk fibroin, preparation process and use thereof. The freeze-dried powder is obtained from silk by degumming, dissolution, dialysis, centrifugation, high temperature and high pressure treatment and freeze-drying. A method of preparing silk fibroin microspheres with polyethylene glycol comprises mixing a silk fibroin solution of 1-30 wt % with a PEG solution of 10-60 w % and incubating the resulting solution. A controlled-release or sustained-release silk fibroin gel formulation includes a gel-state carrier and a drug dispersed/adsorbed therein, the carrier is a silk fibroin gel formed by blending with LMW-PEG.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: January 14, 2020
    Inventors: Xiaoqin Wang, Jian Liu, Jianbing Wu, Cheng Qian, Zhaozhu Zheng, Shaozhe Guo, Fuxin Shi, David Kaplan
  • Patent number: 10517955
    Abstract: Disclosed are proteasome inhibitors, fibroblast activation protein (FAP)-activated prodrugs of proteasome inhibitors, and pharmaceutically acceptable salts of the inhibitors and prodrugs. Also disclosed are related pharmaceutical compositions, and methods of using the inhibitors and prodrugs and compositions thereof, for example, in treating cancer or other cell proliferative diseases. In vitro and in vivo methods of quantifying the expression of FAP in a biopsy sample and a mammal, respectively, are also disclosed.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: December 31, 2019
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Hung-sen Lai, Sarah E. Poplawski
  • Patent number: 10514382
    Abstract: A facile laboratory-based method and kit for use in accordance with the method is disclosed. The method allows for the localisation of biomolecules comprising a conjugatable sulfhydryl group to be localised to the surface of cells, such as red blood cells, as lipid conjugates. The method obviates the need to purify the lipid-conjugated biomolecule before contacting with the cells.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: December 24, 2019
    Inventors: Nikolai Vladimirovich Bovin, Stephen Micheal Henry, Ludmila Baidakova Rodionov
  • Patent number: 10508136
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: December 17, 2019
    Inventor: Amir Zlotkin